Your browser doesn't support javascript.
loading
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches.
Navarro, Carla; Ortega, Ángel; Santeliz, Raquel; Garrido, Bermary; Chacín, Maricarmen; Galban, Néstor; Vera, Ivana; De Sanctis, Juan Bautista; Bermúdez, Valmore.
Afiliación
  • Navarro C; Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela.
  • Ortega Á; Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela.
  • Santeliz R; Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela.
  • Garrido B; Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela.
  • Chacín M; Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla 080002, Colombia.
  • Galban N; Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela.
  • Vera I; Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela.
  • De Sanctis JB; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacký University Olomouc, 779 00 Olomouc, Czech Republic.
  • Bermúdez V; Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla 080002, Colombia.
Pharmaceutics ; 14(6)2022 Jun 19.
Article en En | MEDLINE | ID: mdl-35745875
The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2022 Tipo del documento: Article País de afiliación: Venezuela Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2022 Tipo del documento: Article País de afiliación: Venezuela Pais de publicación: Suiza